Bayer sticks to bone metastasis drug estimate after setback Ruby Khatun Khatun6 Dec 2017 9:15 AM ISTBERLIN: Bayer is sticking to its peak sales estimate for bone metastasis drug Xofigo despite a setback in a late-stage drug trial, the head of the...